Literature DB >> 7622887

Chromosomal restriction fragment length polymorphism analysis of Escherichia coli strains causing recurrent urinary tract infections in young women.

T A Russo1, A Stapleton, S Wenderoth, T M Hooton, W E Stamm.   

Abstract

To determine whether recurrent, symptomatic urinary tract infections (UTIs) in a given individual are due to the same or different strains, 71 Escherichia coli strains that caused recurrent UTIs were prospectively collected from 23 infection-prone young women and studied by chromosomal restriction fragment length polymorphism (RFLP) analysis using pulsed-field gel electrophoresis. Thirty-five strains from women with first-episode UTIs were also studied. Overall, 30 (68%) of 44 recurrent UTIs were caused by a strain previously identified in that person. In contrast, 32 of 35 strains from first-episode UTIs had unique RFLP profiles. Analysis of a subset of subjects established that the majority of recurrent UTIs were due to reinfection, not persistence of the pathogen within the urinary tract, and suggested that the colonic flora was the reservoir for these reinfecting strains.

Entities:  

Mesh:

Year:  1995        PMID: 7622887     DOI: 10.1093/infdis/172.2.440

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  72 in total

1.  Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics.

Authors:  Matthew G Blango; Matthew A Mulvey
Journal:  Antimicrob Agents Chemother       Date:  2010-03-15       Impact factor: 5.191

Review 2.  ppGpp conjures bacterial virulence.

Authors:  Zachary D Dalebroux; Sarah L Svensson; Erin C Gaynor; Michele S Swanson
Journal:  Microbiol Mol Biol Rev       Date:  2010-06       Impact factor: 11.056

Review 3.  The Vaginal Microbiota and Urinary Tract Infection.

Authors:  Ann E Stapleton
Journal:  Microbiol Spectr       Date:  2016-12

Review 4.  Invasion of Host Cells and Tissues by Uropathogenic Bacteria.

Authors:  Adam J Lewis; Amanda C Richards; Matthew A Mulvey
Journal:  Microbiol Spectr       Date:  2016-12

Review 5.  Covert operations of uropathogenic Escherichia coli within the urinary tract.

Authors:  Jean M Bower; Danelle S Eto; Matthew A Mulvey
Journal:  Traffic       Date:  2005-01       Impact factor: 6.215

6.  A killed, genetically engineered derivative of a wild-type extraintestinal pathogenic E. coli strain is a vaccine candidate.

Authors:  Thomas A Russo; Janet M Beanan; Ruth Olson; Stacy A Genagon; Ulrike MacDonald; John J Cope; Bruce A Davidson; Brian Johnston; James R Johnson
Journal:  Vaccine       Date:  2007-02-05       Impact factor: 3.641

7.  Similarity and divergence of phylogenies, antimicrobial susceptibilities, and virulence factor profiles of Escherichia coli isolates causing recurrent urinary tract infections that persist or result from reinfection.

Authors:  Yanping Luo; Yanning Ma; Qiang Zhao; Leili Wang; Ling Guo; Liyan Ye; Youjiang Zhang; Jiyong Yang
Journal:  J Clin Microbiol       Date:  2012-10-03       Impact factor: 5.948

8.  Escherichia coli from urine of female patients with urinary tract infections is competent for intracellular bacterial community formation.

Authors:  Corinne K Garofalo; Thomas M Hooton; Steven M Martin; Walter E Stamm; Joseph J Palermo; Jeffrey I Gordon; Scott J Hultgren
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

9.  A conserved PapB family member, TosR, regulates expression of the uropathogenic Escherichia coli RTX nonfimbrial adhesin TosA while conserved LuxR family members TosE and TosF suppress motility.

Authors:  Michael D Engstrom; Christopher J Alteri; Harry L T Mobley
Journal:  Infect Immun       Date:  2014-06-16       Impact factor: 3.441

10.  Highly resistant metabolically deficient dwarf mutant of Escherichia coli is the cause of a chronic urinary tract infection.

Authors:  Konrad Trülzsch; Harald Hoffmann; Christiane Keller; Sören Schubert; Lutz Bader; Jürgen Heesemann; Andreas Roggenkamp
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.